These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7580862)

  • 1. Acromegaly: unravelling a complex disease.
    O'Halloran DJ; Shalet SM
    Growth Regul; 1995 Sep; 5(3):119-24. PubMed ID: 7580862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acromegaly: multifaceted clinical presentation of a rare disease of the elderly. Report of two cases with long-term follow-up].
    Foppiani L; Del Monte P; Ruelle A; Marugo A; Bernasconi D
    Recenti Prog Med; 2006 Apr; 97(4):200-4. PubMed ID: 16729489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
    Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
    Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma knife radiosurgery for acromegaly--long-term experience.
    Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L
    Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence supporting surgery as treatment of choice for acromegaly.
    Fahlbusch R; Honegger J; Buchfelder M
    J Endocrinol; 1997 Oct; 155 Suppl 1():S53-5. PubMed ID: 9389996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors.
    Shi Y; Tang D; Deng J; Su C
    Chin Med J (Engl); 1998 Oct; 111(10):891-4. PubMed ID: 11189233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The critical parameters in GH excess.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A follow-up of 130 patients with acromegaly in a single centre.
    Bolanowski M; Zatonska K; Kaluzny M; Zielinski G; Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Daroszewski J; Szymczak J; Podgorski JK
    Neuro Endocrinol Lett; 2006 Dec; 27(6):828-32. PubMed ID: 17187024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes and mortality of 94 patients with acromegaly.
    Trepp R; Stettler C; Zwahlen M; Seiler R; Diem P; Christ ER
    Acta Neurochir (Wien); 2005 Mar; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M; Matovinovic M; Vrkljan M
    Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of acromegaly].
    Beauregard H; Somma M; Rasio E; Serri O; Aris-Jilwan N; Comtois R; Long H; Abribat T; Boucher A; Hardy J
    Union Med Can; 1993; 122(6):489-95. PubMed ID: 8303792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.